Cost-and Risk-Benefit considerations in the management of clinical stage I nonseminomatous testicular tumors

Jack Baniel, Bruce J. Roth, Richard Foster, John P. Donohue

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: The high curability of clinical stage I nonseminomatous germ cell tumors (NSGCTs) and the availability of equally effective management options (retroperitoneal lymph node dissection [RPLND] and surveillance) allows for treatment decisions based on secondary end points, including short- and long-term toxicity and cost relative to benefit. The purpose of this study was to perform cost-benefit and risk-benefit analyses of management options in clinical stage I NSGCT using data from the literature and Indiana University. Methods: The overall costs for 100 patients undergoing a primary RPLND were compared with the total costs of 100 patients managed by surveillance for clinical stage I disease. These two options were then analyzed in terms of survival, late relapse, acute and chronic toxicity (including fertility), and perioperative morbidity. Results: The overall costs of these two approaches were essentially identical. The two options were similar in terms of survival, although RPLND demonstrated superiority in terms of fertility, toxicity, and late relapse. Conclusions: The choice of nerve-sparing RPLND or surveillance in a clinical stage I NSGCT patient cannot be made on the basis of cost as a discriminator. Instead, the decision should be made based on patient desires, physician expertise, biological predictors, and short- and long-term toxicity.

Original languageEnglish
Pages (from-to)86-93
Number of pages8
JournalAnnals of Surgical Oncology
Volume3
Issue number1
StatePublished - 1996

Fingerprint

Testicular Neoplasms
Cost-Benefit Analysis
Lymph Node Excision
Costs and Cost Analysis
Fertility
Recurrence
Survival
Morbidity
Physicians
Nonseminomatous germ cell tumor

Keywords

  • Complications
  • Cost-benefit analysis
  • Late relapse fertility
  • Management
  • Nonseminomatous germ cell tumors
  • Risk-benefit analysis
  • Testis cancer

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Cost-and Risk-Benefit considerations in the management of clinical stage I nonseminomatous testicular tumors. / Baniel, Jack; Roth, Bruce J.; Foster, Richard; Donohue, John P.

In: Annals of Surgical Oncology, Vol. 3, No. 1, 1996, p. 86-93.

Research output: Contribution to journalArticle

@article{db5cb7c0ae1f47028516daf91aa3337c,
title = "Cost-and Risk-Benefit considerations in the management of clinical stage I nonseminomatous testicular tumors",
abstract = "Background: The high curability of clinical stage I nonseminomatous germ cell tumors (NSGCTs) and the availability of equally effective management options (retroperitoneal lymph node dissection [RPLND] and surveillance) allows for treatment decisions based on secondary end points, including short- and long-term toxicity and cost relative to benefit. The purpose of this study was to perform cost-benefit and risk-benefit analyses of management options in clinical stage I NSGCT using data from the literature and Indiana University. Methods: The overall costs for 100 patients undergoing a primary RPLND were compared with the total costs of 100 patients managed by surveillance for clinical stage I disease. These two options were then analyzed in terms of survival, late relapse, acute and chronic toxicity (including fertility), and perioperative morbidity. Results: The overall costs of these two approaches were essentially identical. The two options were similar in terms of survival, although RPLND demonstrated superiority in terms of fertility, toxicity, and late relapse. Conclusions: The choice of nerve-sparing RPLND or surveillance in a clinical stage I NSGCT patient cannot be made on the basis of cost as a discriminator. Instead, the decision should be made based on patient desires, physician expertise, biological predictors, and short- and long-term toxicity.",
keywords = "Complications, Cost-benefit analysis, Late relapse fertility, Management, Nonseminomatous germ cell tumors, Risk-benefit analysis, Testis cancer",
author = "Jack Baniel and Roth, {Bruce J.} and Richard Foster and Donohue, {John P.}",
year = "1996",
language = "English",
volume = "3",
pages = "86--93",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Cost-and Risk-Benefit considerations in the management of clinical stage I nonseminomatous testicular tumors

AU - Baniel, Jack

AU - Roth, Bruce J.

AU - Foster, Richard

AU - Donohue, John P.

PY - 1996

Y1 - 1996

N2 - Background: The high curability of clinical stage I nonseminomatous germ cell tumors (NSGCTs) and the availability of equally effective management options (retroperitoneal lymph node dissection [RPLND] and surveillance) allows for treatment decisions based on secondary end points, including short- and long-term toxicity and cost relative to benefit. The purpose of this study was to perform cost-benefit and risk-benefit analyses of management options in clinical stage I NSGCT using data from the literature and Indiana University. Methods: The overall costs for 100 patients undergoing a primary RPLND were compared with the total costs of 100 patients managed by surveillance for clinical stage I disease. These two options were then analyzed in terms of survival, late relapse, acute and chronic toxicity (including fertility), and perioperative morbidity. Results: The overall costs of these two approaches were essentially identical. The two options were similar in terms of survival, although RPLND demonstrated superiority in terms of fertility, toxicity, and late relapse. Conclusions: The choice of nerve-sparing RPLND or surveillance in a clinical stage I NSGCT patient cannot be made on the basis of cost as a discriminator. Instead, the decision should be made based on patient desires, physician expertise, biological predictors, and short- and long-term toxicity.

AB - Background: The high curability of clinical stage I nonseminomatous germ cell tumors (NSGCTs) and the availability of equally effective management options (retroperitoneal lymph node dissection [RPLND] and surveillance) allows for treatment decisions based on secondary end points, including short- and long-term toxicity and cost relative to benefit. The purpose of this study was to perform cost-benefit and risk-benefit analyses of management options in clinical stage I NSGCT using data from the literature and Indiana University. Methods: The overall costs for 100 patients undergoing a primary RPLND were compared with the total costs of 100 patients managed by surveillance for clinical stage I disease. These two options were then analyzed in terms of survival, late relapse, acute and chronic toxicity (including fertility), and perioperative morbidity. Results: The overall costs of these two approaches were essentially identical. The two options were similar in terms of survival, although RPLND demonstrated superiority in terms of fertility, toxicity, and late relapse. Conclusions: The choice of nerve-sparing RPLND or surveillance in a clinical stage I NSGCT patient cannot be made on the basis of cost as a discriminator. Instead, the decision should be made based on patient desires, physician expertise, biological predictors, and short- and long-term toxicity.

KW - Complications

KW - Cost-benefit analysis

KW - Late relapse fertility

KW - Management

KW - Nonseminomatous germ cell tumors

KW - Risk-benefit analysis

KW - Testis cancer

UR - http://www.scopus.com/inward/record.url?scp=0029690762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029690762&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 86

EP - 93

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 1

ER -